INTRODUCTION: CPFA is currently used in the treatment of severe sepsis with the intention of removing the proinflammatory mediators from the systemic circulation. Some evidence exist about the bilirubin adsorbing ability of the neutral styrenic resin which is part of the extracorporeal circuit of CPFA. The aim of this study is to assess efficacy and safety of CPFA in extracorporeal detoxification of liver toxins in patients affected by acute or acute-on-chronic liver failure. METHODS: 9 patients (age 23 - 61 years) with acute (n = 3) or acute-on-chronic (n = 6) liver failure were enrolled. A total of 22 CPFA treatments were carried out. Each CPFA treatment lasted 6 hours. Unfractionated heparin was used as anticoagulation of the extracorporeal circuit in 7 patients; citrate anticoagulation with the concomitant infusion of calcium chloride in 2 of them. The number of treatment for each patient was established on his/her clinical status. The reduction ratios per session of bilirubin and bile acids were considered. Hemoglobin, platelets, white blood cells, coagulation tests, urea, creatinine, and electrolytes were also checked on starting CPFA and at the end of CPFA, as biocompatibility measures. RESULTS: All sessions were well tolerated by the patients. Alcohol was the most common etiology of the liver injury (n = 6), 1 patient was affected by acute cholangitis and Fisher-Evans syndrome, 1 had a viral etiology, and 1 patient had a postoperative jaundice. Median reduction rate per session for total bilirubin was 28% (range 2.2 – 40); for direct bilirubin was 31.4 (range 8.5 – 48.6); for indirect bilirubin was 29.1% (range 6.6 – 65); for bile acids was 30.6% (16.7 – 59.6); for lactic acid was 30% (range -57.2%-55.6%). In six out of nine patients was observed a recovery of liver function. At one year of follow-up 2 patients died during the hospitalization; 6 patients are followed like outpatients and 1 of them is no more in the waiting list for the transplant; the last one is in course of treatment. CONCLUSIONS: Although CPFA is a non-standardized technique for the liver depuration, its use in patients with acute or acute-on-chronic liver failure has shown favorable effects on safety and efficacy in terms of detoxification. Thus it is considerable a “bridge technique” toward the liver transplant and the recovery of basal liver function.
Coupled plasma filtration and adsorption (CPFA) for extracorporeal detoxification during acute or acute on chronic liver failure / Ullo, I; Zappulo, F; Bini, C; Bruno, P; Scrivo, A; Donati, G; Bolondi, L; Piscaglia, F; Simoni, P; La Manna, G. - In: BLOOD PURIFICATION. - ISSN 0253-5068. - 44:(2017), pp. 182-182.
Coupled plasma filtration and adsorption (CPFA) for extracorporeal detoxification during acute or acute on chronic liver failure
Donati G;
2017
Abstract
INTRODUCTION: CPFA is currently used in the treatment of severe sepsis with the intention of removing the proinflammatory mediators from the systemic circulation. Some evidence exist about the bilirubin adsorbing ability of the neutral styrenic resin which is part of the extracorporeal circuit of CPFA. The aim of this study is to assess efficacy and safety of CPFA in extracorporeal detoxification of liver toxins in patients affected by acute or acute-on-chronic liver failure. METHODS: 9 patients (age 23 - 61 years) with acute (n = 3) or acute-on-chronic (n = 6) liver failure were enrolled. A total of 22 CPFA treatments were carried out. Each CPFA treatment lasted 6 hours. Unfractionated heparin was used as anticoagulation of the extracorporeal circuit in 7 patients; citrate anticoagulation with the concomitant infusion of calcium chloride in 2 of them. The number of treatment for each patient was established on his/her clinical status. The reduction ratios per session of bilirubin and bile acids were considered. Hemoglobin, platelets, white blood cells, coagulation tests, urea, creatinine, and electrolytes were also checked on starting CPFA and at the end of CPFA, as biocompatibility measures. RESULTS: All sessions were well tolerated by the patients. Alcohol was the most common etiology of the liver injury (n = 6), 1 patient was affected by acute cholangitis and Fisher-Evans syndrome, 1 had a viral etiology, and 1 patient had a postoperative jaundice. Median reduction rate per session for total bilirubin was 28% (range 2.2 – 40); for direct bilirubin was 31.4 (range 8.5 – 48.6); for indirect bilirubin was 29.1% (range 6.6 – 65); for bile acids was 30.6% (16.7 – 59.6); for lactic acid was 30% (range -57.2%-55.6%). In six out of nine patients was observed a recovery of liver function. At one year of follow-up 2 patients died during the hospitalization; 6 patients are followed like outpatients and 1 of them is no more in the waiting list for the transplant; the last one is in course of treatment. CONCLUSIONS: Although CPFA is a non-standardized technique for the liver depuration, its use in patients with acute or acute-on-chronic liver failure has shown favorable effects on safety and efficacy in terms of detoxification. Thus it is considerable a “bridge technique” toward the liver transplant and the recovery of basal liver function.File | Dimensione | Formato | |
---|---|---|---|
Blood purif abst 2017.pdf
Accesso riservato
Dimensione
206.1 kB
Formato
Adobe PDF
|
206.1 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris